The short answer
CagriSema was filed with the FDA in December 2025 on the REDEFINE programme. Novo Nordisk expected a decision in the fourth quarter of 2026 (report of 4 November 2026); none had been announced by 21 November 2026. REDEFINE 4's failure to demonstrate non-inferiority against tirzepatide does not by itself block approval, because approval is assessed against placebo-controlled evidence.
Key facts
- Filed with FDA
- December 2025
- Supporting trials
- REDEFINE 1 and REDEFINE 2
- Expected decision
- Q4 2026 (Novo Nordisk, 4 November 2026)
- PDUFA date
- Not publicly confirmed (21 November 2026)
- REDEFINE 4
- NCT06131437: non-inferiority not met
- REDEFINE 1
- 22.7% / 20.4% at 68 weeks
- UK status
- No MHRA authorisation
What an approval is actually assessed on
Whether a medicine is safe and effective for its proposed indication, judged largely against placebo-controlled evidence. That is what REDEFINE 1 and REDEFINE 2 provide. A comparative trial against a competitor answers a different question (how it ranks), which matters commercially and to prescribers rather than to the basic approvability decision.
So what did REDEFINE 4 change
The commercial picture rather than the regulatory one. A compound entering a market where the established option performed better in a direct comparison faces a harder argument with prescribers and payers, regardless of what its label says. That is a real consequence and it is not the same as a regulatory obstacle.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Where the filing stands
Submitted to the FDA in December 2025 on the REDEFINE Phase 3 programme. On 4 November 2026 Novo Nordisk said it expected a decision in the fourth quarter of 2026. As of 21 November 2026 no decision and no PDUFA date had been made public. If approved it would be the first once-weekly GLP-1 and amylin analogue combination for weight management.
Why the amylin approach is not settled by this
REDEFINE 4 compared a specific two-molecule combination at a specific dose pair against tirzepatide 15 mg. It did not test amylin as a mechanism. Single-molecule GLP-1 and amylin agonists such as amycretin are in Phase 3 development, and their results will speak to the target in a way this trial could not.
The UK position
CagriSema holds no MHRA authorisation and is not available in the UK. A US approval would not change that. The MHRA assesses separately, and UK availability additionally depends on NICE appraisal for NHS funding, which is a further and distinct process.
What none of this concerns
Research material. CagriSema is an investigational medicine under regulatory review, composed of two licensed-medicine components administered in registered trials. Nothing supplied here relates to it or is an alternative to any weight-management medicine.
Frequently asked questions
Does a failed head-to-head block approval?
No. Approval is assessed largely against placebo-controlled evidence, which REDEFINE 1 and 2 provide. A comparative trial answers a commercial question.
When is the FDA decision expected?
Novo Nordisk said on 4 November 2026 that it expected one in the fourth quarter of 2026. None had been announced by 21 November 2026, and no PDUFA date has been made public.
Is CagriSema available in the UK?
No. It holds no MHRA authorisation, and a US approval would not change that.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- TrialClinicalTrials.gov · CagriSema compared to tirzepatide (NCT06131437)clinicaltrials.gov
- TrialClinicalTrials.gov · REDEFINE 1 (NCT05567796)clinicaltrials.gov
- RefNovo Nordisk: financial report for the first nine months of 2026, 4 November 2026sec.gov
- RefNovo Nordisk: news and company announcementsnovonordisk.com
- RefMHRA: Medicines and Healthcare products Regulatory Agencygov.uk
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Searching a Trial Name Often Finds the Wrong TrialREDEFINE 4 has no acronym in ClinicalTrials.gov - searching for it returns REDEFINE 1, 2 and 3. How to find and check a registration properly.
- Accelerated Approval Is a Conditional StatementApproval on a surrogate endpoint, with confirmatory evidence required afterwards. Why that is a genuinely different decision from a standard approval.
- What the MHRA Found in a Northampton WarehouseOctober 2025: tens of thousands of empty pens, raw ingredients and over 2,000 unlicensed retatrutide and tirzepatide pens ready for dispatch.
- The Scale of UK Medicines EnforcementAlmost 20 million doses and nearly £45m of illegal medicines seized in 2025, including more than 5,000 illegally traded GLP-1 products.
- The EMA Opinion on Oral Semaglutide for Weight ManagementOn 21 May 2026 the CHMP recommended adding oral tablets to Wegovy's authorisation in four strengths. What a positive opinion is, and what it is not.